# Time to peak THC and CBD levels in plasma: fasting and non-fasting

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/d46-png-time-to-peak-thc-and-cbd-levels-in-plasma-fasting-and-non-fasting/
> **Published:** 2026-09-04T23:01:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:46:10-04:00
> **Clinical Summary:** How long THC and CBD take to reach peak plasma levels when fasting versus after food, with metabolites and a comparison table of peak and nadir concentrations.

---

[← Back to Timing Summary Hub](https://cedclinic.com/topic-timing/)

Table of Contents

- [🔍 CED Perspective Lens: Time to peak THC and CBD levels in plasma: fasting and non-fasting](#_CED_Perspective_Lens_Time_to_peak_THC_and_CBD_levels_in_plasma_fasting_and_non-fasting)
- [Time to Peak Levels of Cannabinoids, Terpenes, and Flavonoids in Plasma](#Time_to_Peak_Levels_of_Cannabinoids_Terpenes_and_Flavonoids_in_Plasma)
- [Time to Peak THC and CBD Levels](#Time_to_Peak_THC_and_CBD_Levels)[Fasting vs. Non-Fasting Conditions](#Fasting_vs_Non-Fasting_Conditions)
- [Metabolites](#Metabolites)
- [Other Cannabinoids, Terpenes, and Flavonoids](#Other_Cannabinoids_Terpenes_and_Flavonoids)
- [Comparison Table of Peak and Nadir Plasma Concentrations](#Comparison_Table_of_Peak_and_Nadir_Plasma_Concentrations)
- [References](#References)
- [Precautionary Note](#Precautionary_Note)[Summary Notes](#Summary_Notes)
- [Unraveling the Time to Peak Levels of Cannabinoids, Terpenes, and Flavonoids in Plasma](#Unraveling_the_Time_to_Peak_Levels_of_Cannabinoids_Terpenes_and_Flavonoids_in_Plasma)[🌐 Explore Related CED Clinical Summary Hubs & Research](#_Explore_Related_CED_Clinical_Summary_Hubs_Research)

#### 🔍 CED Perspective Lens: Time to peak THC and CBD levels in plasma: fasting and non-fasting

Dr. Benjamin Caplan, MD

**🌱 Clinical Focus:**
 Detailed evidence review on time to peak thc and cbd levels in plasma: fasting and non-fasting, physiology, and therapeutic applications.
 

**💡 Clinical Guidance:**
 Dosing considerations, bioavailability pathways, and evidence-grounded risk management.
 

**📖 Research & Data:**
 Preserving authoritative charts, diagrams, clinical tables, and scientific reference data.
 

## Time to Peak Levels of Cannabinoids, Terpenes, and Flavonoids in Plasma

## Time to Peak THC and CBD Levels

### Fasting vs. Non-Fasting Conditions

Fasting conditions generally result in quicker absorption of [THC](https://cedclinic.com/topic-cannabinoids/) and CBD when taken orally due to reduced competition for metabolizing enzymes in the liver. The time to peak plasma concentration for orally-administered THC in fasting conditions can range from 1 to 2 hours, compared to 2-4 hours under non-fasting conditions (Huestis, 2007; Ohlsson et al., 1986). For CBD, the time to peak concentration is roughly similar to THC, but slightly delayed in non-fasting conditions (Millar et al., 2018).

### Metabolites

[THC](https://cedclinic.com/topic-cannabinoids/) metabolites like 11-OH-THC and THC-COOH have a longer duration in the bloodstream, peaking at around 6-10 hours post-administration (Huestis, 2007).

## Other Cannabinoids, Terpenes, and Flavonoids

For other cannabinoids like CBG and CBN, peak plasma concentrations can vary but typically occur between 1-3 hours (Brenneisen et al., 1996). [Terpenes](https://cedclinic.com/topic-terpenes/) such as myrcene and limonene peak around 0.5-1 hour after inhalation (Fischedick et al., 2010). Flavonoids are less studied but are thought to have a quick peak time within 1-2 hours (Baron, 2018).

## Comparison Table of Peak and Nadir Plasma Concentrations

Compound
Time to Peak (Fasting)
Time to Peak (Non-Fasting)
Time to Nadir
Reference

THC
1-2 hrs
2-4 hrs
6-10 hrs
Huestis, 2007

CBD
1-2 hrs
2-3 hrs
4-6 hrs
Millar et al., 2018

CBG
1-2 hrs
1-3 hrs
4-6 hrs
Brenneisen et al., 1996

CBN
1-2 hrs
1-3 hrs
4-6 hrs
Brenneisen et al., 1996

Myrcene
0.5-1 hr
N/A
1-2 hrs
Fischedick et al., 2010

Limonene
0.5-1 hr
N/A
1-2 hrs
Fischedick et al., 2010

Flavonoids
1-2 hrs
N/A
2-4 hrs
Baron, 2018

## References

- Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. *Chemistry & Biodiversity*, 4(8), 1770-1804.

- Ohlsson, A., Lindgren, J. E., Wahlen, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980). Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. *Clinical Pharmacology & Therapeutics*, 28(3), 409-416.

- Millar, S. A., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2018). A systematic review of cannabidiol dosing in clinical populations. *British Journal of Clinical Pharmacology*, 84(9), 1888-1900.

- Brenneisen, R., Egli, A., Elsohly, M. A., Henn, V., & Spiess, Y. (1996). The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. *International Journal of Clinical Pharmacology and Therapeutics*, 34(10), 446-452.

- Fischedick, J. T., Hazekamp, A., Erkelens, T., Choi, Y. H., & Verpoorte, R. (2010). Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. *Phytochemistry*, 71(17-18), 2058-2073.

## Precautionary Note

For individuals with certain medical conditions such as liver disease, cardiovascular issues, or psychiatric conditions, the pharmacokinetics of cannabinoids could differ significantly. It is advised for such patients to consult [Dr. Caplan](https://www.BenjaminCaplan.com) at [CED Clinic](https://www.CEDclinic.com) for personalized, evidence-based care.

📗 Note: This diagram’s your starting point, the book’s your marathon. Get your running shoes on [and](https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana/dp/1637742673/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=&sr=)[click this link 📗](https://amzn.to/4a35lhE)

[https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana/dp/1637742673/ref=sr_1_1?crid=3DJRYIYQCIXOG&keywords=Benjamin+Caplan&qid=1695733542&sprefix=benjamin+caplan%2Caps%2C78&sr=8-1](https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana/dp/1637742673/ref=sr_1_1?crid=3DJRYIYQCIXOG&keywords=Benjamin+Caplan&qid=1695733542&sprefix=benjamin+caplan%2Caps%2C78&sr=8-1)[Unlock the world of medical cannabis with The Doctor-Approved Cannabis Handbook.](https://amzn.to/4a35lhE)

### Summary Notes

### Unraveling the Time to Peak Levels of Cannabinoids, Terpenes, and Flavonoids in Plasma

The pharmacokinetics of cannabinoids, including THC and CBD, along with terpenes and flavonoids present in cannabis, play a crucial role in their therapeutic efficacy and overall effects on the body. Understanding the time to peak plasma levels of these compounds is vital for optimizing their medical and recreational use, ensuring safety, and tailoring [dosage](https://cedclinic.com/topic-dosage/) to individual needs.

The absorption and subsequent peak plasma levels of THC, CBD, and other cannabis compounds can vary significantly depending on the method of administration, such as inhalation, oral [ingestion](https://cedclinic.com/topic-edibles-pathways/), or topical application. Each method influences the bioavailability and metabolism of these compounds, affecting how quickly and effectively they are absorbed into the bloodstream.

Factors such as the individual’s metabolism, the dosage, and the specific cannabis strain used can all impact the time to reach peak plasma concentrations. Additionally, the interaction between cannabinoids and [terpenes](https://cedclinic.com/topic-terpenes/), known as the entourage effect, may influence absorption rates and the pharmacological profile of cannabis.

[Terpenes](https://cedclinic.com/topic-terpenes/) and flavonoids, while less studied than cannabinoids, contribute to the therapeutic properties of cannabis and follow their own unique pharmacokinetic paths. Understanding the bioavailability and plasma concentration curves of these compounds is essential for comprehending their role in cannabis’s overall effects.

Recent studies and clinical trials continue to shed light on the complex pharmacokinetics of cannabis compounds. These insights are crucial for medical professionals to tailor treatments and for consumers to make informed decisions about cannabis use.

As research progresses, new methods for measuring and analyzing the plasma levels of cannabinoids, terpenes, and flavonoids are being developed, offering more precise and comprehensive data. The clinical implications of understanding peak plasma levels extend to [dosage](https://cedclinic.com/topic-dosage/) optimization, minimizing adverse effects, and improving therapeutic outcomes for a variety of conditions.

The exploration of peak plasma levels in cannabinoids, [terpenes](https://cedclinic.com/topic-terpenes/), and flavonoids represents a dynamic area of cannabis research. Future directions promise to deepen our understanding of these compounds’ interactions and effects, paving the way for more effective and personalized cannabis-based therapies.

[← Back to Timing Summary Hub](https://cedclinic.com/topic-timing/)

#### 🌐 Explore Related CED Clinical Summary Hubs & Research

[😴 Sleep & Insomnia Hub →](https://cedclinic.com/topic-cannabis-sleep-insomnia/)
[🧬 Bioavailability Hub →](https://cedclinic.com/topic-bioavailability-pathway-decisions/)
[💊 Clinical Dosing Hub →](https://cedclinic.com/topic-dosage/)
[⚡ Pain Control Hub →](https://cedclinic.com/topic-pain-control/)

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).